Filtered By:
Source: Oncology
Drug: Taxotere
This page shows you your search results in order of date.
Order by Relevance | Date
Total 50 results found since Jan 2013.
Neoadjuvant triplet chemotherapy with docetaxel, cisplatin plus 5-FU vs docetaxel, cisplatin plus S-1 for advanced esophageal squamous cell carcinoma: Propensity score matched analysis
CONCLUSIONS: Neoadjuvant DCS therapy for resectable advanced ESCC did not result in significantly higher clinical and pathological response than neoadjuvant DCF therapy. However, neoadjuvant DCS therapy for resectable ESCC required comparatively shorter hospital stays and incurred lower costs, making it an attractive therapeutic option.PMID:37708864 | DOI:10.1159/000533790
Source: Oncology - September 14, 2023 Category: Cancer & Oncology Authors: Junya Kitadani Toshiyasu Ojima Keiji Hayata Taro Goda Akihiro Takeuchi Shinta Tominaga Naoki Fukuda Tomoki Nakai Hiroki Yamaue Manabu Kawai Source Type: research
Retrospective study of treatment patterns and natural history of patients with T1a/b N0 TNBCs-A single-institution experience
CONCLUSIONS: In our cohort, all patients with T1a/b node- TNBCs were treated with adjuvant chemotherapy and had favorable outcomes even when treated with anthracycline-sparing regimens.PMID:37527637 | DOI:10.1159/000533149
Source: Oncology - August 1, 2023 Category: Cancer & Oncology Authors: Langfeier Liu Nicholas Lewis Weihong Sun Junmin Whiting Susan Hoover Ricardo L B Costa Source Type: research
Neo-Adjuvant Management of Adenocarcinoma of Esophagus and Esophago-Gastric Junction - Review of Randomised Evidence and Definition of Optimum Treatment Algorithm
Oncology. 2023 Apr 4. doi: 10.1159/000527716. Online ahead of print.ABSTRACTBACKGROUND: Neoadjuvant chemotherapy (nCT) or chemoradiotherapy (CRT) are accepted standards of care for the management of adenocarcinoma (AC) of esophagus and gastro-esophageal junction (GOJ).SUMMARY: The MRC-OEO2 study established the role of 2 cycles of neoadjuvant cisplatin/fluoropyrimidine (FP). More recently, the FLOT-AIO4 study demonstrated the superiority of peri-operative FLOT chemotherapy (5FU, oxaliplatin and docetaxel) compared to ECX (epirubicin, cisplatin and capecitabine) regime. The results from the pivotal CROSS study established n...
Source: Oncology - April 4, 2023 Category: Cancer & Oncology Authors: Mohan Hingorani Rebecca Goody Georgios Bozas Khwaja Zahid David James Mitton Prashant Jain Vincent Wong Rajarshi Roy Source Type: research
